Merck to further study Keytruda in prostate cancer after early success

Merck & Co Inc said on Thursday it was launching three late-stage studies for its cancer immunotherapy Keytruda as a combination treatment for prostate cancer after the drug showed anti-tumor activity in an early-stage trial.